Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mountain Valley MD Holdings Inc C.MVMD

Alternate Symbol(s):  MVMDF

Mountain Valley MD Holdings Inc. is a Canada-based biotech company, which is focused on advancing solutions to optimize human, animal, and plant health. The Company is focused on implementation, licensing and reselling of key technologies and formulations, such as Quicksome oral formulation and delivery technologies, Quicksol solubility formulation technology, and Agrarius, a novel agricultural plant signaling technology. Quicksome technology utilizes proprietary formulations and stabilizing molecules to encapsulate and formulate active ingredients into efficient product formats. Quicksol technology covers all solubilized macrocyclic lactones that could be applied in multiple viral applications that could impact human and animal health globally. Agrairus agricultural plant signaling technology is used as application to agricultural crops to naturally increase yields, reduce fertilizer usage, and enhance general resilience to pests and climate change.


CSE:MVMD - Post by User

Comment by Baratheonon Jan 27, 2021 9:19am
191 Views
Post# 32397483

RE:RE:https://ceo.ca/@newswire/mountain-valley-md-proceeding-with-

RE:RE:https://ceo.ca/@newswire/mountain-valley-md-proceeding-with-
As well as less dose (drug) needed, their treatment may also reduce speed recovery and so lower mortality rate from Covid as well, given this statement:

"MVMD expects that the upcoming BSL-4 lab study will demonstrate meaningful dose sparing in two important ways; a reduction in the required Active Pharmaceutical Ingredient (API) Ivermectin due to the applications of the Company's technology, and the shorter course to complete viral clearance."
<< Previous
Bullboard Posts
Next >>